Verrica Pharmaceuticals (VRCA) said Friday its development and commercialization partner Torii Pharmaceutical submitted a new drug application in Japan for TO-208, marketed as Ycanth in the US, to treat molluscum contagiosum skin infection.
The company said a phase 3 study in Japan of TO-208 in patients with molluscum contagiosum met its primary efficacy endpoint and showed that the drug's safety profile is consistent with prior studies in the US.
Verrica said it entered into an exclusive license agreement with Torii in 2021 for the development and commercialization of TO-208 for the treatment of molluscum and common warts in Japan.
Verrica shares were more than 9% higher in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。